Van Gelder T, Daane C R, Vaessen L M, Hesse C J, Mochtar B, Balk A H, Weimar W
Department of Internal Medicine, University Hospital Rotterdam, The Netherlands.
Transpl Int. 1994;7 Suppl 1:S556-8. doi: 10.1111/j.1432-2277.1994.tb01442.x.
BT 563, a murine anti-IL-2R MoAb, was found to be more potent than anti-Tac in inhibiting proliferation in the mixed lymphocyte reaction. Results obtained with 33B3.1 in these experiments were similar to those with BT 563. The anti-IL-2R MoAb 2A3 was shown to be a suitable agent for monitoring the effect of BT 563 on peripheral blood. IL-2R-positive cells were not detected in peripheral blood samples from 1 h after the first dose until 8 days after the last dose. Plasma trough levels were measured in patients receiving 5 or 10 mg daily. The administration of BT 563 to allograft recipients did not lead to clinically significant side effects.
BT 563是一种鼠抗人白细胞介素-2受体单克隆抗体，在抑制混合淋巴细胞反应中的增殖方面，其效力比抗Tac更强。在这些实验中，用33B3.1得到的结果与用BT 563得到的结果相似。抗人白细胞介素-2受体单克隆抗体2A3被证明是监测BT 563对外周血作用的合适试剂。从首剂给药后1小时直至末次给药后8天，在外周血样本中均未检测到白细胞介素-2受体阳性细胞。对每日接受5或10毫克剂量的患者测量了血浆谷浓度。给同种异体移植受者施用BT 563未导致具有临床意义的副作用。
